✦ LIBER ✦

Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy

✍ Scribed by N. Niitsu; M. Umeda

Book ID: 114792160
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 390 KB
Volume: 57
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1996.tb01384.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

A multicenter phase II trial of etoposid

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

✍ Sun Jin Sym; Dae Ho Lee; Hye Jin Kang; Seung Hyun Nam; Ho Young Kim; Seok Jin Ki 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 292 KB

A phase II trial of oral etoposide with

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

✍ Jorge E. Romaguera; M. Alma Rodriguez; Frederick B. Hagemeister; Peter McLaughli 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 491 KB

Feasibility and Efficacy of High-Dose Me

Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma

✍ Li-na Han; Jin Zhou; Takayuki Hirose; Yosuke Imai; Takuro Ishiguro; Takaaki Chou 📂 Article 📅 2006 🏛 Carden Jennings Publishing 🌐 English ⚖ 137 KB

Etoposide in combination with intermedia

Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy

✍ Dr J. S. Whelan; C. L. Davis; A. Z. S. Rohatiner; M. Leahy; P. K. Maccallum; R. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 510 KB

Thirty-four patients with refractory or recurrent high grade non-Hodgkin's lymphoma (NHL) or acute leukemia were treated with a combination of etoposide, 100 mg/mZ daily, and ara C, 1 g/m2 twice daily, for 5 days (VPARAC). This therapy was given in the anticipation that remissions thus achieved woul

Gemcitabine, Busulfan and Melphalan (Gem

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

✍ Y. Nieto; R.B. Jones; U. Popat; B. Andersson; B. Valdez; P. Thall; E.J. Shpall; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB